| OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin L Chen, Y Shu, X Liang, EC Chen, SW Yee, AA Zur, S Li, L Xu, ... Proceedings of the National Academy of Sciences 111 (27), 9983-9988, 2014 | 226 | 2014 |
| Transporters involved in metformin pharmacokinetics and treatment response X Liang, KM Giacomini Journal of pharmaceutical sciences 106 (9), 2245-2250, 2017 | 139 | 2017 |
| Genome‐wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response CC Wen, SW Yee, X Liang, TJ Hoffmann, MN Kvale, Y Banda, ... Clinical Pharmacology & Therapeutics 97 (5), 518-525, 2015 | 130 | 2015 |
| Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin EC Chen, X Liang, SW Yee, EG Geier, SL Stocker, L Chen, KM Giacomini Molecular pharmacology 88 (1), 75-83, 2015 | 113 | 2015 |
| Metformin is a substrate and inhibitor of the human thiamine transporter, THTR-2 (SLC19A3) X Liang, HC Chien, SW Yee, MM Giacomini, EC Chen, M Piao, J Hao, ... Molecular pharmaceutics 12 (12), 4301-4310, 2015 | 106 | 2015 |
| Metabolomic and genome‐wide association studies reveal potential endogenous biomarkers for OATP1B1 SW Yee, MM Giacomini, CH Hsueh, D Weitz, X Liang, S Goswami, ... Clinical Pharmacology & Therapeutics 100 (5), 524-536, 2016 | 92 | 2016 |
| Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin S Goswami, SW Yee, S Stocker, JD Mosley, M Kubo, R Castro, JA Mefford, ... Clinical Pharmacology & Therapeutics 96 (3), 370-379, 2014 | 78 | 2014 |
| Discovery of competitive and noncompetitive ligands of the organic cation transporter 1 (OCT1; SLC22A1) EC Chen, N Khuri, X Liang, A Stecula, HC Chien, SW Yee, Y Huang, ... Journal of medicinal chemistry 60 (7), 2685-2696, 2017 | 65 | 2017 |
| Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content X Liang, SW Yee, HC Chien, EC Chen, Q Luo, L Zou, M Piao, A Mifune, ... PLoS biology 16 (4), e2002907, 2018 | 56 | 2018 |
| Interaction of 2, 4-diaminopyrimidine–containing drugs including fedratinib and trimethoprim with thiamine transporters MM Giacomini, J Hao, X Liang, J Chandrasekhar, J Twelves, JA Whitney, ... Drug Metabolism and Disposition 45 (1), 76-85, 2017 | 41 | 2017 |
| Pharmacometabolomic assessment of metformin in non-diabetic, African Americans DM Rotroff, NO Oki, X Liang, SW Yee, SL Stocker, DG Corum, M Meisner, ... Frontiers in Pharmacology 7, 135, 2016 | 37 | 2016 |
| Transporters in drug development: International transporter consortium update on emerging transporters of clinical importance MJ Zamek‐Gliszczynski, V Sangha, H Shen, B Feng, MB Wittwer, ... Clinical Pharmacology & Therapeutics 112 (3), 485-500, 2022 | 29 | 2022 |
| The next frontier in ADME science: Predicting transporter-based drug disposition, tissue concentrations and drug-drug interactions in humans F Storelli, M Yin, AR Kumar, MK Ladumor, R Evers, PP Chothe, ... Pharmacology & Therapeutics 238, 108271, 2022 | 23 | 2022 |
| In vitro hepatic uptake in human and monkey hepatocytes in the presence and absence of serum protein and its in vitro to in vivo extrapolation X Liang, Y Park, N DeForest, J Hao, X Zhao, C Niu, K Wang, B Smith, ... Drug Metabolism and Disposition 48 (12), 1283-1292, 2020 | 18 | 2020 |
| Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates … X Liang, Y Lai Expert Opinion on Drug Metabolism & Toxicology 17 (8), 869-886, 2021 | 9 | 2021 |
| Role of transporters in drug disposition and drug-drug interactions X Liang, KML Staiger, E Riddle, J Hao, Y Lai Identification and Quantification of Drugs, Metabolites, Drug Metabolizing …, 2020 | 6 | 2020 |
| In Vivo Hepatic Enhancer Elements in the Human ABCG2 Locus NADLK Rachel J. Eclov, Mee J. Kim, Robin P. Smith, Xiaomin Liang Drug Metabolism and Disposition 45 (2), 208-215, 2017 | 6 | 2017 |
| Predicting changes in the pharmacokinetics of CYP3A‐metabolized drugs in hepatic impairment and insights into factors driving these changes MK Ladumor, F Storelli, X Liang, Y Lai, OJ Enogieru, PP Chothe, R Evers, ... CPT: Pharmacometrics & Systems Pharmacology 12 (2), 261-273, 2023 | 5 | 2023 |
| Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys Y Cheng, X Liang, J Hao, C Niu, Y Lai Clinical and Translational Science 14 (5), 1924-1934, 2021 | 5 | 2021 |
| Interpretation of protein-mediated uptake of statins by hepatocytes is confounded by the residual statin-protein complex M Yin, K Ishida, X Liang, Y Lai, JD Unadkat Drug Metabolism and Disposition 51 (10), 1381-1390, 2023 | 4 | 2023 |
